Finanzen von GRI Bio Inc (GRI)GRIGRI Bio Inc

Evaluating the bottom line, GRI Bio Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -142.02%, provide a clear picture of how effectively GRI converts its operational activities into shareholder value.

In the context of the broader market, GRI competes directly with industry leaders such as REVB and APVO. With a market capitalization of $4.53M, it holds a leading position in the sector. When comparing efficiency, GRI's gross margin of N/A stands against REVB's N/A and APVO's N/A. Such benchmarking helps identify whether GRI Bio Inc is trading at a premium or discount relative to its financial performance.

The company has shown a decrease in net losses, with Q1 2026 losses down to $2.0 million from $3.0 million in Q1 2025, and cash reserves have improved to $11.0 million, up from $8.2 million at the end of 2025, indicating better liquidity.